Update on Targeted Therapy in Medullary Thyroid Cancer

Update on Targeted Therapy in Medullary Thyroid Cancer

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven by mutations in the REarranged during Transfection (RET) proto-oncogene. The recent expansion of the armamentarium of R...

Full description

Bibliographic Details
Main Authors: Christian Okafor, Julie Hogan, Margarita Raygada, Barbara J. Thomas, Srivandana Akshintala, John W. Glod, Jaydira Del Rivero
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Endocrinology
Subjects:
medullary thyroid cancer (MTC)
MEN2
calcitonin
tyrosine kinase inhibitor
clinical trials
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.708949/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.708949/full

Similar Items